236 related articles for article (PubMed ID: 10571603)
1. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors.
Fouad YM; Katz PO; Castell DO
Aliment Pharmacol Ther; 1999 Nov; 13(11):1467-71. PubMed ID: 10571603
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
Nzeako UC; Murray JA
Aliment Pharmacol Ther; 2002 Jul; 16(7):1309-16. PubMed ID: 12144581
[TBL] [Abstract][Full Text] [Related]
3. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.
Katz PO; Anderson C; Khoury R; Castell DO
Aliment Pharmacol Ther; 1998 Dec; 12(12):1231-4. PubMed ID: 9882031
[TBL] [Abstract][Full Text] [Related]
4. Nocturnal gastric acid breakthrough is not associated with night-time gastroesophageal reflux in GERD patients.
Weigt J; Kandulski A; Büsch F; Malfertheiner P
Dig Dis; 2009; 27(1):68-73. PubMed ID: 19439964
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis.
Raghu G; Freudenberger TD; Yang S; Curtis JR; Spada C; Hayes J; Sillery JK; Pope CE; Pellegrini CA
Eur Respir J; 2006 Jan; 27(1):136-42. PubMed ID: 16387946
[TBL] [Abstract][Full Text] [Related]
6. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.
Xue S; Katz PO; Banerjee P; Tutuian R; Castell DO
Aliment Pharmacol Ther; 2001 Sep; 15(9):1351-6. PubMed ID: 11552905
[TBL] [Abstract][Full Text] [Related]
7. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
Miner PB
Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
[TBL] [Abstract][Full Text] [Related]
8. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.
Franco MT; Salvia G; Terrin G; Spadaro R; De Rosa I; Iula VD; Cucchiara S
Dig Liver Dis; 2000 Nov; 32(8):660-6. PubMed ID: 11142573
[TBL] [Abstract][Full Text] [Related]
9. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
Castell D; Bagin R; Goldlust B; Major J; Hepburn B
Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
[TBL] [Abstract][Full Text] [Related]
11. Relationship of severity of gastroesophageal reflux disease with gastric acid secretory profile and esophageal acid exposure during nocturnal acid breakthrough: a study using 24-h dual-channel pH-metry.
Ghoshal UC; Chourasia D; Tripathi S; Misra A; Singh K
Scand J Gastroenterol; 2008; 43(6):654-61. PubMed ID: 18569981
[TBL] [Abstract][Full Text] [Related]
12. Ineffective esophageal motility: clinical, manometric, and outcome characteristics in patients with and without abnormal esophageal acid exposure.
Shetler KP; Bikhtii S; Triadafilopoulos G
Dis Esophagus; 2017 Jun; 30(6):1-8. PubMed ID: 28475749
[TBL] [Abstract][Full Text] [Related]
13. Esophageal acid exposure on proton pump inhibitors in unselected asymptomatic gastroesophageal reflux disease patients.
Grigolon A; Cantù P; Savojardo D; Conte D; Penagini R
J Clin Gastroenterol; 2008 Oct; 42(9):969-73. PubMed ID: 18719508
[TBL] [Abstract][Full Text] [Related]
14. Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms.
Fouad YM; Katz PO; Hatlebakk JG; Castell DO
Am J Gastroenterol; 1999 Jun; 94(6):1464-7. PubMed ID: 10364008
[TBL] [Abstract][Full Text] [Related]
15. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.
Egan LJ; Myhre GM; Mays DC; Dierkhising RA; Kammer PP; Murray JA
Aliment Pharmacol Ther; 2003 Jun; 17(12):1521-8. PubMed ID: 12823155
[TBL] [Abstract][Full Text] [Related]
16. Nocturnal gastric acidity pattern in gastro-oesophageal reflux disease with or without oesophagitis.
Sozzi M; Valentini M; Poletti M; Bertolissi E; Serraino D; Bovero E; De Iaco F
Ital J Gastroenterol; 1995; 27(8):413-8. PubMed ID: 8775466
[TBL] [Abstract][Full Text] [Related]
17. [Function of oesophagus and gastro-oesophageal reflux in patients with cystic fibrosis].
Höhne S; Wachter R; Merkel N; Hesse V; Finke R
Z Gastroenterol; 2014 Apr; 52(4):343-7. PubMed ID: 24718938
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of gastro-esophageal reflux disease in patients with difficult to control asthma and effect of proton pump inhibitor therapy on asthma symptoms, reflux symptoms, pulmonary function and requirement for asthma medications.
Sandur V; Murugesh M; Banait V; Rathi PM; Bhatia SJ; Joshi JM; Kate A
J Postgrad Med; 2014; 60(3):282-6. PubMed ID: 25121368
[TBL] [Abstract][Full Text] [Related]
19. Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease.
Lambert R
Aliment Pharmacol Ther; 1997 Aug; 11(4):651-62. PubMed ID: 9305472
[TBL] [Abstract][Full Text] [Related]
20. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
Katz PO; Hatlebakk JG; Castell DO
Aliment Pharmacol Ther; 2000 Jun; 14(6):709-14. PubMed ID: 10848653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
